Lineage Cell Therapeutics Inc (NYSE American:LCTX)
| 1.01 Delayed Data As of Dec 04 |  +0.01 / +1.00%Today’s Change | 0.93 Today|||52-Week Range 1.58 | -13.68% Year-to-Date |
Five Year Financial Summary
| All Currency in US Dollars | 4 Year Trend | |||||
|---|---|---|---|---|---|---|
2015 | 2016 | 2017 | 2018 | |||
| Revenue and Income | Net Revenues | 7.0M | 5.9M | 3.5M | 1.4M | |
| Cost of Goods Sold | 1.1M | 358.0K | 168.0K | 302.0K | ||
| Depreciation And Amortization | 6.3M | 4.8M | 3.3M | 3.3M | ||
| Operating Expenses | Gross Income | -405.0K | 808.0K | -6.0K | -2.2M | |
| General Expenses | 65.4M | 59.8M | 40.7M | 42.4M | ||
| Research And Development | 37.3M | 32.5M | 21.7M | 18.8M | ||
| Total Operating Expenses | 72.8M | 64.9M | 44.1M | 46.0M | ||
| Non-Operating Expenses | Operating Income | -65.8M | -59.0M | -40.7M | -44.6M | |
| Extraordinary Credit | 0.00 | 0.00 | 17.7M | 78.5M | ||
| Extraordinary Charge | 0.00 | 0.00 | -2.8M | -87.3M | ||
| Pre-Tax Equity Earnings | -35.0K | 29.7M | -- | -- | ||
| Interest Expense On Debt | 465.0K | 747.0K | 692.0K | -- | ||
| Other Expenses | 3.5M | 48.6M | 3.2M | 5.5M | ||
| Income Taxes, Minority Interest and Extra Items | Pre-Tax Income | -62.7M | 18.6M | -23.3M | -47.1M | |
| Income Taxes | -4.5M | 0.00 | 0.00 | -346.0K | ||
| Minority Interest | -11.1M | -15.0M | -3.3M | -794.0K | ||
| Preferred Dividend | -415.0K | 0.00 | 0.00 | 0.00 | ||
| Net Income | -47.0M | 33.6M | -20.0M | -46.0M | ||
| Shares To Calculate EPS | Shares To Calculate EPS | 79.7M | 97.3M | 114.5M | 126.9M | |
| Shares To Calculate EPS Diluted | 79.7M | 99.6M | 114.5M | 126.9M | ||
| Earnings Per Share | EPS | -$0.59 | $0.34 | -$0.17 | -$0.36 | |
| EPS Diluted | -$0.59 | $0.34 | -$0.17 | -$0.36 | ||
